Dehydrojuncusol

Research use only, not for human use.

Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.

Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.

Dehydrojuncusol (Huh-7 cells were infected with HCV in cell culture; 0-9.4 μM; 48 hours) inhibits HCV infection in a dose-dependent manner.Dehydrojuncusol inhibits HCV infection in Primary human hepatocytes (PHH).The EC50 of dehydrojuncusol is 1.35μM when added continuously, 8.21μM when added during inoculation, and 1.53μM when added postinoculation, confirming the major effect of the molecule at the postinoculation step. The toxicity of the compound on Huh-7 cells is also tested in parallel at different time points (24h, 48h, and 72h). The results shows that the CC50 of Dehydrojuncusol Is approximately 75.6μM, which is much higher than the active dose, yielding a selective index of 56.Dehydrojuncusol is able to inhibit RNA replication of two frequent daclatasvir-resistant mutants (L31M or Y93H in NS5A). Dehydrojuncusol inhibits HCV RNA replication.

——

——

Others

Other Targets

——

——

——

117824-04-1

264.3

C18H16O2

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years